Medtronic's Corevalve Shows Subclavian Access Success In Patients Contraindicated For Femoral Approach

Medtronic, Inc. (NYSE: MDT) announced new data presented today on the safety and effectiveness of Medtronic's CoreValve system via a novel, subclavian approach. The data reported procedural success of 100 percent; 24- hour survival of 100 percent; and 30-day survival of 89 percent.